Hello everyone. Welcome and thank you for joining this presentation of the Q-linea AB Q3 report. You have Stuart Gander here, President and CEO, and I'm joined by my CFO, Christopher Samuelson. So we'll do this a little bit differently following our traditional process here.
Just a quick disclaimer that will be taken as read and understood, moving ahead to the topics for today. So I will start, as usual, with a commercial update.
I will share some of the feedback that we're getting from customers in our various interactions and some of the word of mouth that's starting to spread very nicely between customers. I will discuss our priorities for Q4 to close out the year strong before I hand it over to Christopher, who will walk through our financials for the quarter. And, as always, we will reserve time for your questions at the end. All right. And for those who just have a few minutes to join us, here are a few key messages I would like to emphasize and ensure everyone walks away with today.
The first point is that the quarter was a strong one regarding consumables. Consumables demand on the instruments. A couple of factors are driving that. Firstly, we had a large number of instruments sold during Q1 and Q2, and one from Q1 was activated during the quarter. Those obviously started to pull through volumes. We continue to see some increases in the same instrument pull-through as customers are getting their protocols finalized and are starting to test on a larger set of their patients. Overall, the commercial pipeline continues to grow very nicely.
The US team has expanded their number of customers that they're speaking to, particularly in the front end of the pipeline, where we expect the contracts to come through, is starting to build up. So we've got over a dozen that are either in evaluation, setting up an evaluation currently, or already in contracting. And those obviously have a fairly near-term outlook with strong visibility on the EMEA side of things.
Franco and his team have also been busy. Italy continues to build up nicely.
We are proceeding with more than ten or so opportunities in Italy.
I'll talk a little bit more later on the deal and how we see the country's dynamics evolving there. But more broadly and perhaps even more exciting, the rest of Europe is continuing to build up. Uh, we do expect some contracts outside Italy during the quarter.
And we have our first evaluations being planned now in Asia and Latin America.
As of now, we are in commercial discussions in over 15 countries, which we're very excited to see. We do expect a strong close to the year. We're pushing hard to close those contracts, especially in North America. It's fairly traditional that institutions do their capital purchase contracting in Q4, or it tends to be back-end weighted. We hope for a strong quarter to close out.
Another dynamic that's driving this is that one of the competitors in the field, Accelerate Diagnostics, has informed their customers that they will not be able to support the installed Pheno base of instruments. And that has triggered a number of conversations. Many of those customers were already looking at ASTar, but it's set a timeline somewhat more urgently for many of the customers. So, we're actively working with those players to engage with them. The other news, on the more internal side of things, we're very pleased with the work that Henrik Jacobson and the operations team have done, pulling in all of the activities needed for our in-house production.
Uh, so that's now completed and signed off.
So going forward, all of our discs will now be fully produced in-house, which significantly decreases the cost of goods per disc on a go-forward basis. And it's good timing because now, as I said, we see the consumables volume starting to pick up.
And then finally, we continue to work on reducing operational costs. This is following the stated plan and strategy that we shift our resources towards market-centric activities, getting in front of customers, getting the word of rapid ASTar and ASTar out into the market, and continue to refine and focus our development activities. Now that we're through some of the major efforts to get ASTar ready, we're working on strategic developments for the ASTar platform, but are simultaneously able to continue reducing resources on the back end, so to speak. So we've brought down spending during Q3 and have a plan going forward to take out an additional roughly 10% of the cost base. So with that, maybe just some orientation for those new to Q-linea AB and the AST market. So Q-linea AB manufactures a flagship diagnostic medical instrument called the ASTar.
It is the leader. We contend in our field for rapid antimicrobial susceptibility testing. It stands out from the others, notably due to its fully automated random access and continuous access platform, which is very well designed for automated lab workflows.
For the modern lab, it has very high clinical reliability, test reproducibility, and a high throughput for labs. It also requires very low hands-on time, which is critical for the busy lab tech in this day and age. Good. So with that, I mean, the journey we're on here.
I've presented this before, so I'll just touch on it briefly.
But again, for those orienting, this is not per se a new set of testing. Antimicrobial susceptibility testing has been around for a long time. There's an established market.
The challenge for the patients and hospitals is that the current standard of care technologies can take several days. 48 to 72 hours to produce an actionable result for the physician.
And essentially, the ASTar produces results within six hours.
So what we anticipate and are starting to see with the increased demand for our tests, is that for critical patients, testing will move towards the rapid AST systems such as ASTar, obviously starting with blood infections that drive sepsis, being one of the most acute critical patient categories. But there are other critical non-blood infections as well that will move over time.
We believe in the transition to rapid AST testing.
So, if you run the rough numbers, we see 5 to 7 million tests in our space, and we see pricing holding up in that target range of $120 to $180 per test fairly consistently now. So that generates a market just for the blood testing of $600 to $900 million that we're opening up here and starting to see grow. And on that note, sales development during the quarter did not close as many contracts as we'd hoped. We have now ended with 17 instruments in active routine use. I did mention that we turned on six of the instruments that were sold earlier. So, it's nice to see that the time to installation and go live is continuing to shorten as we anticipated. The contracts we secured were both in the US and Italy. And we do see that there is a strong build-up.
As I mentioned earlier, especially in the US, contracts are entering their final stage. So I do expect the quarter to close out strong. We continue to push hard towards our target of 30 instruments for the year. Obviously, before, when we talked about this last quarter, we had in front of us the tender in Italy with nine instruments.
So we're openly disappointed, of course, that our previously successful appeal of the tender decision was overturned by a court in Rome. So, whilst there has been no final award of that tender, there may be developments on that front. We now give lower visibility for sure on those nine instruments. So, with that, you know, the upper end of our range last time, 30 to 40, we think is quite unlikely. However, that said, we do have plenty of instruments in the pipeline here that we're working through. So the 30 is within reach on a strong Q4 close here. That's supported by these 15 countries that are now active. Obviously, our direct team in the US and Italy are working hard on their own pipeline of customers. We work through a network of distributors and agents in other countries around the world, and Franco has been leading many of those efforts. And what we see here now is conversations we've had earlier starting to warm up. And distributors are coming to Q-linea AB with customer-specific cases and evaluations that they want to run. So our posture on geographic expansion has been a measured one to conserve resources and be very thoughtful about where we put time and energy. Uh, so we're directing both towards areas where antimicrobial resistance is particularly high, i.e. There's strong clinical need, but also there's a clear willingness to pay and a flagship customer willing to adopt in the market. In my experience, once the top institutions in any given country adopt, you start to get a rethinking of the standard of care. And from there, let's say the proverbial snowball starts to roll.
So our approach now is to work with distributors to identify those flagship institutions and invest in a very targeted way with our partners into those relationships to then grow in the market. I hope to see that during Q4, instruments will be distributed to more markets, setting up for evaluations that will convert in the early part of next year. On that note, we have already shipped to Saudi Arabia. That's the third evaluation ongoing in the Middle East with our partner Ameco, which has built a very robust pipeline in that region. Expect to see that 2026 will be a strong year.
We are now represented in the United Arab Emirates, Kuwait, and Saudi Arabia. Obviously, these are three of the cornerstone markets for that region, which tend to set standards. I think that bodes well for the outlook. I already spoke about the US pipeline. I would say one dynamic there is that, obviously, Accelerate had a fairly robust installed base of customers that are now accustomed to using rapid AST and seeing the clinical benefits of it. And those customers can no longer be served with consumables.
They've turned to Q-linea AB for an alternative. So we're working with several of them now on an accelerated contracting process. As I've talked about several times, it can sometimes be a bit of a convoluted process in the US with large institutions. Given the clinical urgency to maintain patient care, we're optimistic that some of these will move through more quickly, which is good. So those are the highlights for the quarter. And, you know, obviously, the substance, let's say, for how we maintain that target of 30 to close out the year.
The team also keeps working at the opening end of the funnel, engaging with customers directly. One of our best avenues to do so remains the face-to-face interaction at conferences, where dozens or even hundreds of customers are accessible, and we can have rich conversations and demonstrate the instrument. Several of these take place over the summer season in the US, with the largest being ADLM in Chicago, where I was present, and the team also represented us at regional shows in Texas and New England. I was also present with the team in Birmingham, UK, for the biannual IBMS conference, where we joined our distributor, Prolab, to catch up with customers there.
The general theme of these is very consistent. We continue to publish materials in the space. That's what these conferences are about, and why customers attend them. They want to see the latest science.
We want to make sure that Q-linea AB is seen at the forefront of that.
The data continues to reinforce the evidence we've demonstrated before regarding the clinical impact of the ASTar in practice, and that body of evidence continues to build. In parallel, our clinical affairs team has been engaging closely with pharmaceutical manufacturers in our industry, particularly those who produce the antibiotics on our panel, which will be used to treat patients. And for us, this represents one of the trickier parts of the development process. There's obviously some cost there, but just getting those formulations ready and stable takes time and specific expertise. We are very pleased that we've now signed development partnerships with three of them.
They will help us with some of the raw materials for that and notably support in developing those formulations. This reduction in time and cost helps us to bring new drugs to market on what we internally call our V3 menu.
We are also very pleased to present the results from our work together this year, showcasing an ultra-rapid workflow. The direct-from-blood approach.
If you recall, the slide I showed earlier is considered the holy grail for our industry.
Direct from blood testing, cutting out the need to incubate the blood culture. So, another 10 or 12 hours.
And the results there were very strong. Obviously, plenty of work remains to be done for developing a commercial product. We're pleased with the work with the team. And the results continue to show that ASTar delivers effectively as part of the workflow. So, you know, on that note of demonstrating the science and listening to the customer, just put one example here. Several presentations were also made at US conferences by our US customers. But as I mentioned, I was over in Birmingham at the IBMS, and one of our customers, Jennifer Monkhouse, presented data from her lab very nicely. It's one where we've seen an increase in usage as this data has demonstrated that the NHS has, perhaps, an appropriately conservative approach to adopting new technologies. They want to see that the clinical evidence is there.
So the lab started using ASTar and has now been able to demonstrate the impact as shown here. I've gotten the nod from their local trust to go ahead and make that available for patients across the system. And there isn't anything, let's say, especially surprising about the numbers here because we keep showing something very similar, but nonetheless, a huge tribute to Jennifer for the great work pulling this together. It reinforces the reduction of time to patient therapy in this case, by around 1.77 days, and every hour counts in sepsis, as we know. And then also the team has made an estimate here on what they determined to be the savings for the trust of €2 million and £2 million.
In parallel, our clinical affairs team has been closely engaging with pharmaceutical manufacturing partners in our industry, particularly those who produce the antibiotics that are on our panel and for which patients will be treated. And I think that's a very important point to highlight since the main constraint for many of the clinicians and labs eager to adopt rapid AST is that the healthcare budget holders are trying to find ways to fund new technologies, and therefore, scrutinizing and showing that health economic case is important. This is another data point for us in what we call our business impact model that we discuss with customers every day. It's a tool that we show to help a hospital see the clinical and economic impact in their facility. But, you know, it's one thing taking it from us. It's another matter when a customer shows it to their own stakeholders and peers in the field, which carries even more weight. It's great to see these coming out. More of these continue to come.
Basically every quarter. So our attention is now really focused here to close strong on 2025. Highlighting three areas, obviously starting with the commercial side, the conversion of the pipeline that I mentioned, the drive to 30 ASTar in the field, is partly, but not entirely, supported by the additional Pheno users that are reaching out to us.
And if we can get those through on a slightly fast-tracked approach.
I mentioned the first evaluations in Asia and Latin America. These are somewhat more distant markets geographically.
Some, perhaps with some language and training challenges, will need to work through.
So, it's a test for our team that's ready and has been preparing for this. So, we'll get some of those going. And then really continuing to drive that consumables pull-through growth on the platform. Obviously, the new installations will achieve that on their own, let's say. But we work closely with customers to discuss with them why and if they stratify customers. Unfortunately, budgets don't allow all customers to use the test for all patients, which is a difficult choice to make in a clinical environment for critical patients. So we work with the customers and try to get them more data so that they can work on that with their stakeholders. So we will continue to do that. This ties into the clinical priorities where our team is focused on those frontline customers. At the same time, we are completing some strategic efforts mentioned earlier, and we're very happy that our internal work is now completed for the version two menu.
So we're ready to submit, waiting for the US government to reopen here.
And we'll hit send more or less right away. And then the work is being presented at IDWeek in Atlanta. I'm actually in Atlanta as I speak here, where we will present the results from using ASTar as a multi-prep workflow tool, which has benefits in both cost and also operator time, and potentially even reliability of preparing things for the end-to-end test. Very excited about that. That provides another avenue for value for our customers.
We're also working to prepare the first publication of results for non-blood AST testing with our research partners. So, there's more to come. We keep alluding to that side of the patient population, since they're potentially even more numerous than blood patients. So we expect to see that having an impact on our business in the very near future. And then on the financial side, I'll turn it over here to Krista to talk through the details. But you know, our commitment is to continue to refine the cost base as we become more efficient in our operations. We have achieved some scale here now so we're able to gain efficiencies. We will work on a couple of key initiatives, such as moving the entire team to our factory location in Uppsala. We currently have two offices in the Uppsala region, so that will generate some savings. Also, I think reducing some of the geographic frictions in the local team there makes us even more efficient. And then some of the external costs as well will continue to decrease both through efficiencies and as projects wind down and we complete those. We are targeting a 10% reduction through 2026, which still gives us the resources we need to drive the commercial agenda and deliver on those strategic projects. Finally, I think Krista will touch on completing the rights issue that we've announced for Q4. So with that, Krista, I will turn it over to you before coming back for questions.